MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526356 | Name: SR 271425

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR 271425 is a novel cytotoxic DNA-interacting agent with broad antitumor activity in preclinical models.

Chemical Structure

SR 271425
SR 271425
CAS#155990-20-8

Theoretical Analysis

MedKoo Cat#: 526356

Name: SR 271425

CAS#: 155990-20-8

Chemical Formula: C22H27N3O3S

Exact Mass: 413.1773

Molecular Weight: 413.54

Elemental Analysis: C, 63.90; H, 6.58; N, 10.16; O, 11.61; S, 7.75

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SR 271425; SR271425; SR-271425; SW-71425; SW-271425; WIN 71425.
IUPAC/Chemical Name
Formamide, N-((1-((2-(diethylamino)ethyl)amino)-7-methoxy-9-oxo-9H-thioxanthen-4-yl)methyl)-
InChi Key
GWLFIMOOGVXSMZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H27N3O3S/c1-4-25(5-2)11-10-24-18-8-6-15(13-23-14-26)22-20(18)21(27)17-12-16(28-3)7-9-19(17)29-22/h6-9,12,14,24H,4-5,10-11,13H2,1-3H3,(H,23,26)
SMILES Code
O=CNCC1=CC=C(NCCN(CC)CC)C(C2=O)=C1SC3=C2C=C(OC)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 413.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lockhart AC, Calvo E, Tolcher AW, Rowinsky EK, Shackleton G, Morrison JG, Rafi R, VerMeulen W, Rothenberg ML. A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors. Am J Clin Oncol. 2009 Feb;32(1):9-14. doi: 10.1097/COC.0b013e318178331b. PubMed PMID: 19194116. 2: Goncalves PH, High F, Juniewicz P, Shackleton G, Li J, Boerner S, LoRusso PM. Phase I dose-escalation study of the thioxanthone SR271425 administered intravenously once every 3 weeks in patients with advanced malignancies. Invest New Drugs. 2008 Aug;26(4):347-54. doi: 10.1007/s10637-008-9135-2. PubMed PMID: 18449472; PubMed Central PMCID: PMC3771109. 3: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. PubMed PMID: 17805439. 4: Soria JC, Dieras V, Girre V, Yovine A, Mialaret K, Armand JP. QTc monitoring during a phase I study: experience with SR271425. Am J Clin Oncol. 2007 Apr;30(2):106-12. PubMed PMID: 17414458. 5: Campone M, Isambert N, Bourbouloux E, Maury S, Monin-Baroille P, Berille J, Fumoleau P. Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors. Cancer Chemother Pharmacol. 2007 Apr;59(5):689-95. PubMed PMID: 17031647. 6: Marasanapalle V, Li X, Polin L, Jasti BR. Novel in vitro model barriers for evaluation of the permeability of antitumor compounds, thioxanthones. Invest New Drugs. 2006 Mar;24(2):111-6. PubMed PMID: 16502352. 7: Poondru S, Zhou S, Rake J, Shackleton G, Corbett TH, Parchment RE, Jasti BR. High-performance liquid chromatographic method for the estimation of the novel investigational anti-cancer agent SR271425 and its metabolites in mouse plasma. J Chromatogr B Biomed Sci Appl. 2001 Aug 5;759(1):175-8. PubMed PMID: 11499623. 8: Corbett TH, Panchapor C, Polin L, Lowichik N, Pugh S, White K, Kushner J, Meyer J, Czarnecki J, Chinnukroh S, Edelstein M, LoRusso P, Heilbrun L, Horwitz JP, Grieshaber C, Perni R, Wentland M, Coughlin S, Elenbaas S, Philion R, Rake J. Preclinical efficacy of thioxanthone SR271425 against transplanted solid tumors of mouse and human origin. Invest New Drugs. 1999;17(1):17-27. PubMed PMID: 10555119.

View History

Betulinic Aldehyde oxime

Betulinic Aldehyde oxime

Featured